Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203919 | 0.84 | CRHR1 (0.51) | CRHR1CNR1 | |
| SCHEMBL5210158 | 0.79 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL7478626 | 0.66 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL5420523 | 0.64 | CRHR1 (0.78) | CRHR1 | |
| SCHEMBL5209552 | 0.64 | HSD11B1 (0.46) | CRHR1 | |
| SCHEMBL5419528 | 0.63 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5208904 | 0.63 | L3MBTL1 (0.40) | CRHR1 | |
| SCHEMBL7220186 | 0.62 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5404092 | 0.62 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5206955 | 0.61 | CRHR1 (0.62) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6747034-B2 | CORTICOTROPIN-RELEASING FACTOR (CRF); SUCH AS 4-CHLORO-2-METHYL-5-NITRO-8-(2,4-DICHLORO)PHENYL-1,7-NAPHTHYRIDINE FOR TREATING STROKE, ANXIETY, DEPRESSION, AND/OR IRRITABLE BOWEL SYNDROME | NEUROCRINE BIOSCIENCES, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | CRHR1 1/4885CNR1 25/4885 |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | CRHR1 1/4885CNR1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.